Anti-Human CTGF Recombinant Antibody (FG-3019) (CAT#: TAB-194CL)

Figure 1 Recombinant human CTGF was analyzed by western blot using FG-3019 antibodies.

FG-3019 specifically bound CTGF without crossreacting with CYR61 or NOV.

Wang, Q., Usinger, W., Nichols, B., Gray, J., Xu, L., Seeley, T. W., ... & Lin, A. (2011). Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis & tissue repair, 4(1), 4.

Figure 2 Hepatic and renal fibrosis in mice receiving transforming growth factor (TGF)-band connective tissue growth factor (CTGF) is ameliorated by FG-3019 treatment.

All agents were administered daily for 20 days beginning one day after birth. Arrowsindicate regions of robust capsular fibrosis inhibited by FG-3019 treatment. Representative images are shown (all haematoxylin and eosin,original magnification × 200).

Wang, Q., Usinger, W., Nichols, B., Gray, J., Xu, L., Seeley, T. W., ... & Lin, A. (2011). Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis & tissue repair, 4(1), 4.

Figure 3 Influence of neutralizing CTGF-specific mAb on CTGF-expressing cells in vitro and in vivo.

TUNEL of paraffin-embedded tumor sections of CTGF-expressing (CE8) xenografts treated with either CTGF-specific mAb FG-3019 were used to assess the influence of CTGF antibody on apoptosis (green, TUNEL-positive apoptotic cells; ×200 magnification).

Dornhöfer, N., Spong, S., Bennewith, K., Salim, A., Klaus, S., Kambham, N., ... & Höckel, M. (2006). Connective tissue growth factor–specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer research, 66(11), 5816-5827.

Figure 4 Influence of neutralizing CTGF-specific mAb on CTGF-expressing cells in vitro and in vivo.

CD31 staining of paraffin-embedded tumor sections of CTGF-expressing (CE8) xenografts treated with either CTGF-specific mAb FG-3019 or vehicle, were used to assess blood vessel density (brown-green, endothelial cells, ×100 magnification).

Dornhöfer, N., Spong, S., Bennewith, K., Salim, A., Klaus, S., Kambham, N., ... & Höckel, M. (2006). Connective tissue growth factor–specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer research, 66(11), 5816-5827.

Figure 1 Anti-Human CTGF Recombinant Antibody (FG-3019) in WB.

Western blot analysis was performed by loading 0.1 µg (lane 1), 0.3 µg(lane 2), and 0.6 µg (lane 3) recombinant human CTGF onto a 12% Tris-HCl polyacrylamide gel.

Figure 2 Anti-Human CTGF Recombinant Antibody (FG-3019) in DB.

Dot Blot analysis of TAB-194CL-L8 was performed by coating with human CTGF antigen.

Figure 3 Anti-Human CTGF Recombinant Antibody (FG-3019) in ELISA.

ELISA analysis of TAB-194CL-L8 was performed by coating with Human CTGF protein, His Tag.